Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Cash (2016 - 2025)

Editas Medicine (EDIT) has disclosed Change in Cash for 11 consecutive years, with $25.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 17.5% to $25.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $68.6 million, a 416.09% increase, with the full-year FY2024 number at $7.9 million, up 144.15% from a year prior.
  • Change in Cash was $25.9 million for Q3 2025 at Editas Medicine, up from -$150000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $215.2 million in Q1 2021 to a low of -$138.3 million in Q3 2023.
  • A 5-year average of $1.3 million and a median of -$150000.0 in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: soared 4804.61% in 2021, then tumbled 434.79% in 2023.
  • Editas Medicine's Change in Cash stood at -$56.4 million in 2021, then decreased by 22.74% to -$69.2 million in 2022, then surged by 159.43% to $41.1 million in 2023, then fell by 13.15% to $35.7 million in 2024, then fell by 27.47% to $25.9 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Change in Cash are $25.9 million (Q3 2025), -$150000.0 (Q2 2025), and $7.2 million (Q1 2025).